Peer Exchange

2017 Changes to the McDonald Criteria: Diagnosing Multiple Sclerosis

Use of MRI in Diagnosing Multiple Sclerosis

Misdiagnosis of Multiple Sclerosis

Cerebrospinal Fluid in Diagnosing Multiple Sclerosis

Unmet Needs in the Management of Migraine

Acute Treatment of Migraine: Traditional Therapies

Evolution of Acute Treatment of Migraine

Acute Treatment of Migraine: Progress With Novel Medications

Use of 5-HT1F Agonists in Acute Treatment of Migraine

Safety of CGRP Receptor Antagonists vs 5-HT1F Agonists

Intranasal DHE in Acute Treatment of Migraine

Patient Selection of Novel Therapies for Migraine Treatment

Role of Neuromodulation for Acute Treatment of Migraine

Patient Selection for Neuromodulation Devices

Behavioral and Lifestyle Strategies for Migraine Management

Diagnosis of Multiple Sclerosis: The McDonald Criteria

Differential Diagnosis of Multiple Sclerosis

MOG-IgG in Multiple Sclerosis

Clinically Isolated Syndrome Versus Multiple Sclerosis

First-Line Therapies for Relapsing Multiple Sclerosis

The Use of Interferon in Multiple Sclerosis

The Use of Glatiramer Acetate in Multiple Sclerosis

Clinical Trials for Cladribine in Multiple Sclerosis

Treating With Cladribine in Multiple Sclerosis

Role of Siponimod in Multiple Sclerosis

Ocrelizumab for the Treatment of Multiple Sclerosis

Role of Ocrelizumab in Europe for Multiple Sclerosis

Role of Diroximel Fumarate in Multiple Sclerosis

Role of Ozanimod in Multiple Sclerosis

Switching Therapies in Multiple Sclerosis

Decision-Making Process for Treating Multiple Sclerosis

The Future of Treating Multiple Sclerosis

Cardiac Amyloidosis Diagnostic Workup

Hypertrophic Cardiomyopathy Historical Prognosis

AL and ATTR Diagnosis: Echo and Noncardiac Biopsy

When Are Heart Biopsies Warranted?

Technetium Pyrophosphate Scan Benefits

Monoclonal Protein Testing and Wild-Type ATTR

Technetium Pyrophosphate Scan Prior to TAVR

AL and ATTR Survival Metrics

Poor Toleration: AL and ATTR Treatment Modification

Cardioversion and Atrial Fibrillation Ablation

Cardiac Amyloidosis: Pacemakers and Defibrillators

Therapy Selection for Congestive Heart Failure

Available ATTR Selective Stabilizers

Cardiomyopathy Management: NSAID Options

TTR Gene Silencers as Cardiomyopathy Treatment

Developing Agents for Cardiac Amyloidosis Management

Overview of Spinal Muscular Atrophy

Phenotypes of Spinal Muscular Atrophy

Newborn Screening for Spinal Muscular Atrophy

Genetic Testing for Spinal Muscular Atrophy

Motor Testing to Assess Patients With SMA

Involvement of Primary Care Physicians in Diagnosing SMA

Pulmonary Care for Patients With Spinal Muscular Atrophy

GI Complications in Patients With Spinal Muscular Atrophy

Multidisciplinary Approach to Treating SMA

Recent Approval of Zolgensma for SMA

STR1VE Trial of Onasemnogene Abeparvovec for SMA

SPR1NT Trial of Onasemnogene Abeparvovec for SMA

Nusinersen for Treatment of SMA

Nusinersen ENDEAR-SHINE and CHERISH-SHINE for SMA

Nusinersen Phase 2 NURTURE Trial for SMA

Risdiplam in Development for SMA

Clinical Trials for Risdiplam for SMA

Final Thoughts on Treating SMA

Overview of Excessive Daytime Sleepiness

Overview of Narcolepsy

Signs and Symptoms of Narcolepsy

Narcolepsy Type 1 and Type 2

Diagnosis of Narcolepsy

Goals of Therapy in Narcolepsy

Nonpharmacologic Therapies for Narcolepsy

Laboratory Testing in Patients with Narcolepsy

Traditional Treatments for Narcolepsy

Pitolisant: Recently FDA Approved for Narcolepsy

Solriamfetol: Recently FDA Approved for Narcolepsy

Deciding Which Drug to Use in Narcolepsy

Insurance Coverage For Drugs to Treat Narcolepsy

Patient Resources Including the Narcolepsy Network

Drugs in Development for Treatment of Narcolepsy

Unmet Needs in the Treatment of Narcolepsy

Advice for Community Physicians Treating Narcolepsy

Referral to a Sleep Specialist to Treat Narcolepsy

Final Thoughts on Treating Narcolepsy